Merck and Samsung Bioepis agree diabetes deal

11-02-2014

Merck and Samsung Bioepis agree diabetes deal

Photo: Copyright © 2009-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.

Pharmaceutical company Merck and Samsung Bioepis, a joint venture between South Korean firm Samsung and Biogen, have agreed to work on a diabetes treatment.


Merck, Samsung Bioepis, MK-1293, Biogen

LSIPR